Acrivon Therapeutics, Inc.

Develops precision cancer therapies by matching patients to drugs using its proteomics platform.

ACRV | NDAQ

Overview

Corporate Details

ISIN(s):: US0048901096
LEI:
Country:: United States of America
Address:: 480 ARSENAL WAY, SUITE 100, 2472 WATERTOWN
Website:: https://acrivon.com/
Sector:: Mining and quarrying
Industry:: Mining of non-ferrous metal ores

Description

Acrivon Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in precision oncology. The company leverages its proprietary Acrivon Predictive Precision Proteomics (AP3) platform to develop targeted cancer therapies. The AP3 platform utilizes phosphoproteomics to analyze the biologic drivers of a patient's cancer, enabling the creation of predictive 'OncoSignature' tests. This method is designed to match drug candidates with patients whose tumors are most likely to respond, aiming to improve therapeutic outcomes beyond what is achievable with genomics. Acrivon's pipeline is led by ACR-368, a selective kinase inhibitor in Phase 2 clinical trials for various solid tumors. The company also advances its internally developed programs and seeks strategic partnerships to apply its AP3 platform to co-develop predictive tests for external drug candidates.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Acrivon Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Acrivon Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for Acrivon Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
Mare Nostrum Comprehensive HR solutions provider for recruitment, temporary work, training, and wage portage.	France	ALMAR
Marubeni Construction Material Lease Co.,Ltd. Leases and sells temporary steel materials and offers engineering for major construction projects.	Japan	9763
MATCHING SERVICE JAPAN CO.,LTD. Specialized recruitment firm connecting legal, finance, and accounting experts with top companies.	Japan	6539
Material Group inc. A professional services firm offering PR consulting, marketing, and brand strategy.	Japan	156A
Medesis Pharma S.A. Develops therapies for CNS disorders and radiation exposure via a drug delivery platform.	France	ALMDP
MEDICINOVA INC Developing small-molecule therapies for neurological, respiratory, and fibrotic diseases.	United States of America	MNOV
Medicofarma Biotech Spolka Akcyjna A biotech R&D company developing innovative drugs and devices with a focus on oncology therapies.	Poland	MDB
Medpace Holdings, Inc. Global CRO providing full-service clinical development to biotech, pharma & medical device industries.	United States of America	MEDP
MedPacto, Inc. Develops biomarker-based precision therapies for oncology and other incurable diseases.	South Korea	235980
Medrx Co.,Ltd. Develops and licenses transdermal drug delivery systems for the pharmaceutical industry.	Japan	4586